The U.S. equity market has been anything but calm in 2025, as several factors, including persistent trade tensions, rising ...

UBS analyst Eliana Merle reaffirmed a Buy rating and a $582 price target for Vertex Pharmaceuticals, praising the adoption of ...

Vertex Pharmaceuticals is riding high on analyst confidence, thanks to its leadership in NAV1.8 inhibitors and smart partnerships. Jefferies analyst Michael Yee recently reaffirmed a Buy rating, ...

US pharma major Eli Lilly (NYSE: LLY) has announced a definitive agreement to acquire SiteOne Therapeutics, a private ...

Eli Lilly has reached a deal to acquire SiteOne Therapeutics that would give it control of a non-opioid pain drug that would ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Four months after Vertex Pharmaceuticals Inc.’s U.S. FDA nod for Journavx (suzetrigine) as the first drug targeting NaV1.8 for treating pain, Eli Lilly and Co. is joining the potential competition via ...

Reshma Kewalramani, Bela Bajaria, Revathi Advaithi and Meena Lakdawala Flynn among women at the top of the global business ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

The deal tees up a pain treatment market rivalry with Vertex Pharmaceuticals as the industry starts to move away from opioids ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

The opioid crisis has made it even more urgent to come up with novel approaches to treating suffering. Finally there’s ...